PNPLA3 RNAi Composition for Targeted NAFLD Gene Silencing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for nonalcoholic fatty liver disease (NAFLD) are limited, and there is a need for therapies that target the underlying cause of hepatic steatosis and its progression to more severe stages like NASH and cirrhosis, particularly focusing on the PNPLA3 gene's role in triglyceride accumulation and fibrogenesis.

Innovation Solution

Development of double-stranded RNAi agents that specifically target and inhibit the expression of the PNPLA3 gene, utilizing modified nucleotides and ligand-conjugated strands to enhance efficacy and stability, facilitating RNA-induced silencing complex-mediated cleavage of PNPLA3 mRNA.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments for NAFLD are used, then weight loss and management of secondary conditions are achieved, but no direct pharmacologic treatment for the underlying cause is available

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidavailability of pharmacologic treatments

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses RNA interference technology as an intermediary mechanism to deliver therapeutic effect. The double-stranded RNA agents act as mediators that specifically target and silence the PNPLA3 gene, providing a direct pharmacologic treatment for the underlying cause of NAFLD rather than just managing symptoms or secondary conditions

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces conventional pharmacologic approaches with a novel RNA-based mechanism. Instead of using traditional small-molecule drugs that target protein products, the invention uses double-stranded RNA agents that directly target mRNA transcripts, utilizing the cellular RNA interference pathway to achieve gene silencing and treat the root cause of the disease

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If RNAi agents are developed to target PNPLA3 gene, then specific inhibition of triglyceride accumulation is achieved, but complexity of the therapeutic approach increases

Engineering Contradiction:

Improvespecificity of gene targetingVSAvoidcomplexity of RNAi agent structure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies local quality by modifying specific regions of the RNAi agent structure. Different portions of the double-stranded RNA molecule are selectively modified with various chemical groups to enhance stability, facilitate delivery, and improve activity while maintaining the core RNA interference function. This localized modification approach allows optimization of specific properties without completely redesigning the entire molecule

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent creates composite RNAi agents by combining different chemical components. The double-stranded RNA structure is复合ed with various modified nucleotides, conjugated ligands, and protective groups to form a composite therapeutic agent that integrates multiple functions: gene targeting, cellular delivery, and enhanced stability in a single molecular construct

Inventive Principle:

Principle #40Composite materials

3Reliability

If modified nucleotides and ligand-conjugated strands are used in RNAi agents, then efficacy and stability are enhanced, but manufacturing complexity increases

Engineering Contradiction:

Improvestability of RNAi agentVSAvoidease of synthesizing modified RNAi agents

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent segments the RNAi agent synthesis into modular components. The double-stranded RNA is constructed from separately synthesized oligonucleotide strands that can be independently modified and then assembled. This segmentation allows each component to be optimized and manufactured separately using established oligonucleotide synthesis techniques, then combined to form the complete therapeutic agent

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent systematically varies chemical parameters of the RNAi agent, such as the type of modified nucleotides, the nature of ligand conjugates, and the position of modifications along the RNA strand. By changing these parameters in a controlled manner, the invention optimizes stability and efficacy while establishing standardized modification patterns that can be replicated in manufacturing

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The RNAi agents effectively inhibit PNPLA3 expression, reducing triglyceride accumulation and mitigating the progression of NAFLD by downregulating the hedgehog signaling pathway, offering a therapeutic approach for NAFLD, NASH, and other PNPLA3-associated diseases.

Implementation Method 1

iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a PNPLA3 gene

Methodology Applied

Scientific EffectRNA interference (RNAi):

Data Source

PatentUS12569511B2Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof

Publication Date: 2026.03.10 ALNYLAM PHARMACEUTICALS INC

AI summary

The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.